Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1646882 | 0.84 | — | — | |
| SCHEMBL31474906 | 0.82 | — | — | |
| SCHEMBL21945778 | 0.80 | — | — | |
| SCHEMBL11522292 | 0.79 | — | — | |
| SCHEMBL11519475 | 0.79 | — | — | |
| SCHEMBL338407 | 0.75 | SMN1; SMN2 (0.33) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL775155 | 0.75 | SMN1; SMN2 (0.33) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL79029 | 0.73 | — | — | |
| SCHEMBL4023703 | 0.73 | SMN1; SMN2 (0.37) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL1760755 | 0.73 | SMN1; SMN2 (0.32) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110177798-B | Catalyst and process for preparing same | 博里利斯股份公司 | 2022-08-30 | — | — | CN | disclosed |
| US-11352376-B2 | Catalysts | BOREALIS AG (AT) | 2022-06-07 | — | — | US | disclosed |
| EP-3541823-B1 | CATALYSTS | BOREALIS AG (AT) | 2020-12-30 | — | — | EP | disclosed |
| US-20190308995-A1 | CATALYSTS | BOREALIS AG (AT) | 2019-10-10 | — | — | US | disclosed |
| EP-3541823-A1 | CATALYSTS | Borealis AG (AT) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018091653-A1 | CATALYST | BOREALIS AG (AT) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018091684-A1 | CATALYSTS | BOREALIS AG (AT) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352376-B2 | Catalysts | SIGMAR1, H1-2, SFN | SMN1; SMN2 3593/4885LMNA 3915/4885ALDH1A1 2139/4885 |
| US-20190308995-A1 | CATALYSTS | SIGMAR1, H1-2, CBR1 | SMN1; SMN2 3745/4885LMNA 3944/4885ALDH1A1 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.